Solution
Theranostics Solutions
Therapeutics + Diagnostics = Theranostics — see what you treat, treat what you see.
Discuss a theranostics programTheranostic care pairs a diagnostic radiotracer with a therapeutic radionuclide that share the same biological target, so a cancer is imaged and confirmed before — and verified after — it is treated. MED I (Thailand) supports theranostic programs across the full chain: isotope production, radiochemistry, imaging, and the radiation-protection infrastructure each requires.
What's included
How theranostic radiotracers work
A targeting molecule binds a specific marker on cancer cells. For diagnosis, it carries an isotope that emits a small, imageable signal; for treatment, the same targeting molecule carries a stronger therapeutic isotope — sparing healthy cells that lack the target.
A proven, expanding toolkit
Radioactive iodine (I-131) has treated thyroid cancer for over 80 years; Lu-177 (2015) and Ac-225 (2016) extended the approach to metastatic castration-resistant prostate cancer and other solid tumors.
Prostate cancer
177Lu-PSMA supports both PET imaging and therapy for metastatic castration-resistant prostate cancer; 225Ac-PSMA is used therapeutically in patients who have not responded to other treatments.
Neuroendocrine tumors
68Ga-DOTATATE and 68Ga-DOTATOC localize neuroendocrine tumors on PET imaging, guiding subsequent targeted radionuclide therapy.
In practice
Planning a theranostics solutions programme?
Tell us what you're building — we'll come back with scope, equipment options and a realistic path to a GMP-compliant facility.